Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Arance

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Breast (Edinburgh, Scotland)|August 9, 2015
Clinical implications of the intrinsic molecular subtypes of breast cancerAleix Prat, Estela Pineda, Barbara Adamo, et al.
The Oncologist|May 21, 2017
Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)Grant A McArthur, Peter Mohr, Paolo Antonio Ascierto, et al.
Cancer Research|February 7, 2007
Ability to acquire drug resistance arises early during the tumorigenesis processErnesto Yagüe, Ana Arance, Loïc Kubitza, et al.
Annals of Diagnostic Pathology|June 16, 2022
Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progressionIrene Moysset, Carla Fuster-Anglada, Paola Castillo, et al.
Melanoma Research|July 22, 2014
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access ProgramAlfonso Berrocal, Ana Arance, Jose Antonio Lopez Martin, et al.
Annals of Translational Medicine|November 12, 2020
<i>TP53</i> mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomasLlucia Alos, Carla Fuster, Paola Castillo, et al.
Cancers|March 10, 2022
Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on SurvivalLorena Villa-Crespo, Sebastian Podlipnik, Natalia Anglada, et al.
The Lancet. Oncology|June 6, 2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyCaroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
ESMO Open|November 16, 2016
Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritisFrancisco Aya, Lydia Gaba, Ivan Victoria, et al.
Cancers|June 27, 2024
Predictive and Prognostic Factors in Melanoma Central Nervous System Metastases-A Cohort StudyEstefania Serra, Álvaro Abarzua-Araya, Ana Arance, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Breast (Edinburgh, Scotland)|August 9, 2015
Clinical implications of the intrinsic molecular subtypes of breast cancerAleix Prat, Estela Pineda, Barbara Adamo, et al.
The Oncologist|May 21, 2017
Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)Grant A McArthur, Peter Mohr, Paolo Antonio Ascierto, et al.
Cancer Research|February 7, 2007
Ability to acquire drug resistance arises early during the tumorigenesis processErnesto Yagüe, Ana Arance, Loïc Kubitza, et al.
Annals of Diagnostic Pathology|June 16, 2022
Immunophenotype of tumor-infiltrating lymphocytes in atypical Spitzoid tumors according to the risk of progressionIrene Moysset, Carla Fuster-Anglada, Paola Castillo, et al.
Melanoma Research|July 22, 2014
Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access ProgramAlfonso Berrocal, Ana Arance, Jose Antonio Lopez Martin, et al.
Annals of Translational Medicine|November 12, 2020
<i>TP53</i> mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomasLlucia Alos, Carla Fuster, Paola Castillo, et al.
Cancers|March 10, 2022
Timeline of Adverse Events during Immune Checkpoint Inhibitors for Advanced Melanoma and Their Impacts on SurvivalLorena Villa-Crespo, Sebastian Podlipnik, Natalia Anglada, et al.
The Lancet. Oncology|June 6, 2013
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyCaroline Robert, Reinhard Dummer, Ralf Gutzmer, et al.
ESMO Open|November 16, 2016
Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritisFrancisco Aya, Lydia Gaba, Ivan Victoria, et al.
Cancers|June 27, 2024
Predictive and Prognostic Factors in Melanoma Central Nervous System Metastases-A Cohort StudyEstefania Serra, Álvaro Abarzua-Araya, Ana Arance, et al.
Pageof 10